

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1204bxd

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAPLUS records now contain indexing from 1907 to the present
NEWS	4	DEC 08	INPADOC: Legal Status data reloaded
NEWS	5	SEP 29	DISSABS now available on STN
NEWS	6	OCT 10	PCTFULL: Two new display fields added
NEWS	7	OCT 21	BIOSIS file reloaded and enhanced
NEWS	8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	9	NOV 24	MSDS-CCOHS file reloaded
NEWS	10	DEC 08	CABA reloaded with left truncation
NEWS	11	DEC 08	IMS file names changed
NEWS	12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS	13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS	14	DEC 17	DGENE: Two new display fields added
NEWS	15	DEC 18	BIOTECHNO no longer updated
NEWS	16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS	17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS	18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS	19	DEC 22	ABI-INFORM now available on STN
NEWS	20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAPLUS
NEWS	22	FEB 05	German (DE) application and patent publication number format changes
NEWS EXPRESS			DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:36:20 ON 19 FEB 2004

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 17:36:31 ON 19 FEB 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 FEB 2004 HIGHEST RN 651705-73-6

DICTIONARY FILE UPDATES: 18 FEB 2004 HIGHEST RN 651705-73-6

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\09937604.str



chain nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23  
24 25 26 27 28

chain bonds :

1-2 1-6 1-7 1-8 2-3 3-4 4-5 8-9 9-10 9-12 10-11 11-17 12-13 13-14  
14-15 15-16 16-25 17-18 18-19 19-20 20-21 21-22 22-23 23-24 25-26 26-27  
27-28

exact/norm bonds :

1-2 1-6 1-7 1-8 4-5 9-12 10-11 11-17 12-13

exact bonds :

2-3 3-4 8-9 9-10 13-14 14-15 15-16 16-25 17-18 18-19 19-20 20-21 21-22  
22-23 23-24 25-26 26-27 27-28


Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS  
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS  
18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS  
26:CLASS 27:CLASS 28:CLASS

L1        STRUCTURE UPLOADED

=> d query

L1                    STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 17:36:47 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED -        2 TO ITERATE

100.0% PROCESSED            2 ITERATIONS                    0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*  
                              BATCH    \*\*COMPLETE\*\*  
PROJECTED ITERATIONS:            2 TO        124  
PROJECTED ANSWERS:                0 TO        0

L2                    0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 17:36:51 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED -        28 TO ITERATE

100.0% PROCESSED            28 ITERATIONS                    4 ANSWERS  
SEARCH TIME: 00.00.01

L3                    4 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'CAPLUS' ENTERED AT 17:36:55 ON 19 FEB 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Feb 2004 VOL 140 ISS 8  
FILE LAST UPDATED: 18 Feb 2004 (20040218/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 6 L3


=> d l4 1-6 abs ibib hitstr

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS ON STN  
AB Vaxfectin, a recently developed adjuvant, was evaluated for its enhancing effect on immunogenicity of a Japanese encephalitis (JE) DNA vaccine plasmid encoding the JE virus premembrane (prM) and envelope (E) genes (designated pcJEME), using BALB/c and ICR mice. Formulation of pcJEME with Vaxfectin provided 28-fold higher neutralizing antibody titers than those induced by pcJEME alone and reduced the amount of pcJEME to one-tenth to induce comparable levels of neutralizing antibody. Use of Vaxfectin did not alter a Th1 type IgG isotype immune response (IgG1 < IgG2a) induced by pcJEME in mice. Thus, Vaxfectin has an ability to enhance immunogenicity of pcJEME and is considered as a useful adjuvant for DNA vaccines in murine exptl. models.

ACCESSION NUMBER: 2003:469912 CAPLUS  
DOCUMENT NUMBER: 139:178416  
TITLE: Enhancing Effect of Vaxfectin on the Ability of a Japanese Encephalitis DNA Vaccine to Induce Neutralizing Antibody in Mice  
AUTHOR(S): Nukuzuma, Chiyoko; Ajiro, Naoko; Wheeler, Carl J.; Konishi, Ei-ji  
CORPORATE SOURCE: Department of Health Sciences, Kobe University School of Medicine, Kobe, Japan  
SOURCE: Viral Immunology (2003), 16(2), 183-189  
CODEN: VIIMET; ISSN: 0882-8245  
PUBLISHER: Mary Ann Liebert, Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 370108-99-9, Vaxfectin  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(Vaxfectin adjuvant enhancement of Japanese encephalitis virus DNA vaccine induction of neutralizing antibodies in mouse model)  
RN 370108-99-9 CAPLUS  
CN 1-Propanaminium, N-(3-aminopropyl)-N,N-dimethyl-2,3-bis[(9Z)-9-tetradecenyl]oxy]-, bromide, mixt. With (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl bis(3,7,11,15-tetramethylhexadecanoate) (1:1) (9CI) (CA INDEX NAME)

CM 1  
CRN 370108-98-8  
CMF C36 H73 N2 O2 . Br

Double bond geometry as shown.



CM 2

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS ON STN  
AB Mice were vaccinated with plasmid DNA (pDNA) encoding antigen 85A (Ag85A), Ag85B, or PstS-3 from Mycobacterium tuberculosis either in saline or formulated for i.m. injections in VCI052:DPyPE (aminopropyl-dimethyl-myristolexyloxy-propanaminium bromide-diphytanoylphosphatidyl-ethanolamine) (Vaxfectin; Vical, Inc., San Diego, Calif.) or for intranasal installations in GAP-DLRIE:DOPE (aminopropyl-dimethyl-bis-dodecyloxy-propanaminium bromide-dioleoylphosphatidyl-ethanolamine). These two novel cationic and neutral colipid formulations were previously reported to be effective adjuvants for pDNA-induced antibody responses. The levels of Ag85-specific total IgG (IgG) and IgG isotypes were all increased 3- to 10-fold by formulation of pDNA in Vaxfectin. The level of production of splenic T-cell-derived Th1-type cytokines (interleukin-2 and gamma interferon) in response to purified Ag85 and to synthetic peptides spanning the entire Ag85A protein was also significantly higher in animals vaccinated with pDNA formulated in Vaxfectin. Cytolytic T-lymphocyte responses generated by pDNA encoding phosphate-binding protein PstS-3 in Vaxfectin were better sustained over time than were those generated by PstS-3 DNA in saline. Intranasal immunization with Ag85A DNA in saline was completely ineffective, whereas administration in GAP-DLRIE:DOPE induced a pos. Th1-type cytokine response; however, the extent of the latter response was clearly lower than that obtained following i.m. immunization with the same DNA dose. Combined i.m. and intranasal administrations in cationic lipids resulted in stronger immune responses in the spleen and, more importantly, in the lungs as well. Finally, formulation in Vaxfectin increased the protective efficacy of the Ag85B DNA vaccine, as measured by reduced relative light unit counts and CFU counts in the spleen and lungs from mice challenged with bioluminescent

M. tuberculosis H37Rv. These results may be of importance for future clin. use of DNA vaccines in humans.


ACCESSION NUMBER: 2002:489711 CAPLUS  
DOCUMENT NUMBER: 138:226501  
TITLE: Improved tuberculosis DNA vaccines by formulation in cationic lipids  
AUTHOR(S): D'Souza, S.; Roaseels, V.; Denis, O.; Tanghe, A.; De Smet, N.; Jurion, F.; Palfliet, K.; Castiglioni, N.; Vanonckelen, A.; Wheeler, C.; Huygen, K.  
CORPORATE SOURCE: Mycobacterial Immunology, Pasteur Institute of Brussels, Brussels, B180, Belg.  
SOURCE: Infection and Immunity (2002), 70(7), 3681-3688  
CODEN: INFIBR; ISSN: 0019-9567  
PUBLISHER: American Society for Microbiology  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 370108-99-9, Vaxfectin  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(tuberculosis DNA vaccines formulated in cationic lipids)  
RN 370108-99-9 CAPLUS  
CN 1-Propanaminium, N-(3-aminopropyl)-N,N-dimethyl-2,3-bis[(9Z)-9-tetradecenyl]oxy]-, bromide, mixt. With (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl bis(3,7,11,15-tetramethylhexadecanoate) (1:1) (9CI) (CA INDEX NAME)

CM 1  
CRN 370108-98-8


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

CRN 201036-16-0  
CMF C45 H90 N O8 P

Absolute stereochemistry.




PAGE 1-B



FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)  
CMF C36 H73 N2 O2 . Br


Double bond geometry as shown.




CM 2

CRN 201036-16-0  
CMF C45 H90 N O8 P

Absolute stereochemistry.



PAGE 1-B



FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS ON STN  
 AB The large number of cytofectin and co-lipid combinations currently used for lipoplex-mediated gene delivery reflects the fact that the optimal cytofectin/co-lipid combination varies with the application. The effects of structural changes in both cytofectin and co-lipid were systematically examined to identify structure-activity relationships. Specifically, alkyl chain length, degree of unsatn. and the head group to which the alkyl side chain was attached were examined to determine their effect on lipoplex structure and biol. activity. The macroscopic lipoplex structure was assessed using a dye-binding assay and the biol. activity was examined using in vitro transfection in three diverse cell lines. Lipoplexes were formulated in three different vehicles currently in use for in vivo delivery of naked plasmid DNA (pDNA) and lipoplex formulations. The changes in dye accessibility were consistent with structural changes in the lipoplex, which correlated with alterations in the formulation. In contrast, transfection activity of different lipoplexes was cell type and vehicle dependent and did not correlate with dye accessibility. Overall, the results show a correlation between transfection and enhanced membrane fluidity in both the lipoplex and cellular membranes.

ACCESSION NUMBER: 2002:325272 CAPLUS  
 DOCUMENT NUMBER: 138:61130  
 TITLE: Synergy between cationic lipid and co-lipid determines the macroscopic structure and transfection activity of lipoplexes  
 AUTHOR(S): Ferrari, Marilyn E.; Rusalov, Denis; Enas, Joel; Wheeler, Carl J.  
 CORPORATE SOURCE: Department of Chemistry, Vical Incorporated, San Diego, CA, 92121, USA  
 SOURCE: Nucleic Acids Research (2002), 30(8), 1808-1816  
 CODEN: NARHAD; ISSN: 0305-1048  
 PUBLISHER: Oxford University Press  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 370108-98-8P 479200-95-8P  
 RL: FRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (synergy between cationic lipid and co-lipid det. the macroscopic structure and transfection activity of lipoplexes)  
 RN 370108-98-8 CAPLUS  
 CN 1-Propanaminium, N-(3-aminopropyl)-N,N-dimethyl-2,3-bis[(9Z)-9-tetradecenyl-1-oxy]-, bromide (9CI) (CA INDEX NAME)

Double bond geometry as shown.


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS ON STN  
 AB Antigen specific immune responses were characterized after i.m. immunization of BALB/c mice with 5 antigen encoding plasmid DNAs (pDNAs) complexed with Vaxfectin, a cationic lipid formulation. Vaxfectin increased IgG titers for all of the antigens with no effect on the CTL responses to the 2 antigens for which CTL assays were performed. Both antigen specific IgG1 and IgG2a were increased, although IgG2a remained greater than IgG1. Furthermore, Vaxfectin had no effect on IFN-γ or IL-4 production by splenocytes re-stimulated with antigen, suggesting that the Th1 type responses typical of i.m. pDNA immunization were not altered. Studies with IL-6 -/- mice suggest that the antibody enhancement is IL-6 dependent and results in a correlative increase in antigen specific antibody secreting cells.

ACCESSION NUMBER: 2001:409275 CAPLUS  
 DOCUMENT NUMBER: 136:198463  
 TITLE: Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization  
 AUTHOR(S): Reyes, L.; Hartikka, J.; Bozoukova, V.; Sukhu, L.; Nishioka, W.; Singh, G.; Ferrari, M.; Enas, J.; Wheeler, C. J.; Manthorpe, M.; Wloch, M. K.  
 CORPORATE SOURCE: Department of Cell Biology, Vical Incorporated, San Diego, CA, 92121, USA  
 SOURCE: Vaccine (2001), 19(27), 3778-3786  
 CODEN: VACCDE; ISSN: 0264-410X  
 PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 370108-99-9, Vaxfectin  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Vaxfectin enhanced antigen-specific antibody titers maintaining Th1 type immune responses to plasmid DNA vaccines)  
 RN 370108-99-9 CAPLUS  
 CN 1-Propanaminium, N-(3-aminopropyl)-N,N-dimethyl-2,3-bis[(9Z)-9-tetradecenyl-1-oxy]-, bromide, mixt. with (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl bis(3,7,11,15-tetramethylhexadecanoate) (1:1) (9CI) (CA INDEX NAME)

CM 1  
 CRN 370108-98-8  
 CMF C36 H73 N2 O2 . Br

Double bond geometry as shown.


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



● Br<sup>-</sup>

RN 479200-95-8 CAPLUS  
 CN 1-Propanaminium, N-(3-aminopropyl)-N,N-dimethyl-2,3-bis[(9Z)-9-octadecenyl-1-oxy]-, bromide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● Br<sup>-</sup>

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




● Br<sup>-</sup>

CM 2


CRN 201036-16-0  
 CMF C45 H90 N O8 P

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B




REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS ON STN  
 AB This report characterizes Vaxfectin, a novel cationic and neutral lipid formulation which enhances antibody responses when complexed with an antigen-encoding plasmid DNA (pDNA). In mice, i.m. injection of Vaxfectin formulated with pDNA encoding influenza nucleoprotein (NP) increased antibody titers 5-20-fold, to levels that could not be reached with pDNA alone. As little as 1 µg of pDNA formulated with Vaxfectin per muscle resulted in higher anti-NP titers than that obtained with 25 µg naked pDNA. The antibody titers in animals injected with Vaxfectin-pDNA remained higher than in the naked pDNA controls for at least 9 mo. The enhancement in antibody titers was dependent on the Vaxfectin dose and was accomplished without diminishing the strong anti-NP cytolytic T cell response typical of pDNA-based vaccines. In rabbits, complexing pDNA with Vaxfectin enhanced antibody titers ≤ 50-fold with needle and syringe injections and also augmented humoral responses when combined with a needle-free injection device. Vaxfectin did not facilitate and/or increase synthesis of β-galactosidase reporter protein in muscle tissue. ELISPOT assays performed on bone marrow cells from vaccinated mice showed that Vaxfectin produced a 3- to 5-fold increase in the number of NP-specific plasma cells. Thus, Vaxfectin should be a useful adjuvant for enhancing pDNA-based vaccinations.


ACCESSION NUMBER: 2001:146642 CAPLUS  
 DOCUMENT NUMBER: 135:330213  
 TITLE: Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens  
 AUTHOR(S): Hartikka, J.; Bozoukova, V.; Ferrari, M.; Sukhu, L.; Enas, J.; Sawdey, M.; Wloch, M. K.; Tonsky, K.; Norman, J.; Manthorpe, M.; Wheeler, C. J.  
 CORPORATE SOURCE: Department of Cell Biology, Vicat Incorporated, San Diego, CA, 92121, USA  
 SOURCE: Vaccine (2001), 19(15-16), 1911-1923  
 CODEN: VACCDE; ISSN: 0264-410X  
 PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 370108-99-9P, Vaxfectin  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens)  
 RN 370108-99-9 CAPLUS  
 CN 1-Propanaminium, N-(3-aminopropyl)-N,N-dimethyl-2,3-bis[(9Z)-9-tetradecenyl]oxy-, bromide, mixt. with (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl bis(3,7,11,15-tetramethylhexadecanoate) (1:1) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 370108-98-8  
 CMF C36 H73 N2 O2 . Br  
 Double bond geometry as shown.

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT


L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



CM 2  
 CRN 201036-16-0  
 CMF C45 H90 N O8 P  
 Absolute stereochemistry.



PAGE 1-B




IT 370108-98-8P, VC 1052  
 RL: FRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens)  
 RN 370108-98-8 CAPLUS  
 CN 1-Propanaminium, N-(3-aminopropyl)-N,N-dimethyl-2,3-bis[(9Z)-9-tetradecenyl]oxy-, bromide (9CI) (CA INDEX NAME)  
 Double bond geometry as shown.

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS ON STN

AB A series of 2,3-dialkylxypropyl quaternary ammonium lipids containing hydroxyalkyl chains on the quaternary amine were synthesized, formulated with dioleoylphosphatidylethanolamine (DOPE) and assayed for their ability to enhance the activity of an intercellular adhesion mol. 1 (ICAM-1) antisense oligonucleotide, ISIS 1570. Cationic liposomes prepared with hydroxyethyl, hydroxypropyl, and hydroxybutyl substituted cationic lipid all enhanced the activity of the ICAM-1 antisense oligonucleotide. Cationic lipids containing hydroxypropyl quaternary amines only marginally enhanced the activity of ISIS 1570. Hydroxyethyl cationic lipids synthesized with dimyristyl (C14:0) and dioleoyl (C18:1) alkyl chains were equally effective. Activity of cationic lipids containing saturated alkyl groups decreased as the chain length increased, i.e. the dimyristyl (C14:0) was more effective than dipalmityl (C16:0) lipid, which was more effective than distearyl (C18:0). The phase transition temperature of cationic lipids containing saturated aliphatic chains was 56 for the distearyl lipid, 42 for the dipalmityl lipid, and 24° for the dimyristyl lipid. Cationic lipids with dioleoyl alkyl chains required DOPE for activity, with optimal activity occurring at 50 mol%. In contrast, a dimyristyl containing cationic lipid did not require DOPE to enhance the activity of ISIS 1570. Formulation with different phosphatidylethanolamine derivs., revealed that optimal activity was obtained with DOPE. These studies demonstrate that several cationic lipid species enhance the activity of phosphorothioate antisense oligonucleotides and provide further information on the mechanism by which cationic lipids enhance the activity of phosphorothioate oligodeoxynucleotides.

ACCESSION NUMBER: 1998:229461 CAPLUS  
 DOCUMENT NUMBER: 129:19588  
 TITLE: Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture  
 AUTHOR(S): Bennett, C. F.; Mirejovsky, D.; Crooke, R. M.; Tsai, Y. J.; Felgner, J.; Sridhar, C. N.; Wheeler, C. J.; Felgner, P. L.  
 CORPORATE SOURCE: ISIS Pharmaceuticals, Carlsbad, CA, 92008, USA  
 SOURCE: Journal of Drug Targeting (1998), 5(3), 149-162  
 CODEN: JDTAEH; ISSN: 1061-186X  
 PUBLISHER: Harwood Academic Publishers  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 207602-65-1  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (structural requirements for cationic liposome mediated phosphorothioate oligonucleotides delivery to cells)  
 RN 207602-65-1 CAPLUS  
 CN 1-Propanaminium, N-(3-aminopropyl)-N,N-dimethyl-2,3-bis[(9Z)-1-oxo-9-octadecenyl]oxy-, bromide (9CI) (CA INDEX NAME)  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

=> fil reg  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
29.85	185.48

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-4.16	-4.16

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 17:38:58 ON 19 FEB 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 FEB 2004 HIGHEST RN 651705-73-6  
DICTIONARY FILE UPDATES: 18 FEB 2004 HIGHEST RN 651705-73-6

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.


Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> s GAP-DMORIE/cn  
L5 1 GAP-DMORIE/CN

=> d 15

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 299207-54-8 REGISTRY  
 CN 1-Propanaminium, N-(2-aminoethyl)-N,N-dimethyl-2,3-bis[(9Z)-9-tetradecenyoxy]-, bromide (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN GAP-DESOLIE  
 FS STEREOSEARCH  
 MF C35 H71 N2 O2 . Br  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Double bond geometry as shown.



3 REFERENCES IN FILE CA (1907 TO DATE)  
 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
6.62	192.10

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-4.16

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 17:39:46 ON 19 FEB 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Feb 2004 VOL 140 ISS 8  
FILE LAST UPDATED: 18 Feb 2004 (20040218/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 299207-54-8/rn  
3 299207-54-8  
0 299207-54-8D  
L6 3 299207-54-8/RN  
(299207-54-8 (NOTL) 299207-54-8D )

=> d l6 abs ibib hitstr


L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN  
AB The present invention relates to pharmaceutical compns. and methods to improve expression of exogenous polypeptides into vertebrate cells in vivo, utilizing delivery of polynucleotides encoding such polypeptides. More particularly, the present invention provides the use of salts, in particular sodium and potassium salts of phosphate, in aqueous solution, and auxiliary agents, in particular detergents and surfactants, in pharmaceutical compns. and methods useful for direct polynucleotide-based polypeptide delivery into the cells of vertebrates.  
ACCESSION NUMBER: 2001:798084 CAPLUS  
DOCUMENT NUMBER: 135:348865  
TITLE: Compositions and methods for in vivo delivery of polynucleotide-based therapeutics  
INVENTOR(S): Hartikka, Jukka; Sukhu, Loretta; Manthorpe, Marston  
PATENT ASSIGNEE(S): Vical Incorporated, USA  
SOURCE: PCT Int. Appl., 176 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001080897	A2	20011101	WO 2001-US12975	20010423
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 2002019358	A1	20020214	US 2001-839574	20010423
EP 1278551	A2	20030129	EP 2001-928741	20010423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
PRIORITY APPLN. INFO.:			US 2000-198823P	P 20000421
			US 2000-253153P	P 20001128
			WO 2001-US12975	W 20010423

IT 299207-54-8, Gap-dmorie  
RL: MOA (Modifier or additive use); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (compns. and methods for in vivo delivery of polynucleotide-based therapeutics)  
RN 299207-54-8 CAPLUS  
CN 1-Propanaminium, N-(2-aminoethyl)-N,N-dimethyl-2,3-bis[(9Z)-9-tetradecenyl]oxy]-, bromide (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● Br<sup>-</sup>

=>

=> d 16 2-3 abs ibib hitstr

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS ON STN  
 AB A method of increasing the strength of the immune response of vector vaccines using an expression vector for the Flt3 ligand is described.  
 The vaccines are made of independent non-integrating expression vectors: one encodes the antigen or a cytokine and the other encodes the Flt3 ligand. The present invention also provides a method broadly directed to improving immune response of a vertebrate in need of immunotherapy by administering in vivo, into a tissue of a vertebrate, a Flt-3 ligand-encoding polynucleotide and one or more antigen- or cytokine-encoding polynucleotides. The polynucleotides are incorporated into the cells of the vertebrate in vivo, and a prophylactically or therapeutically effective amount of a Flt-3 ligand and one or more antigens is produced in vivo.

ACCESSION NUMBER: 2001:101291 CAPLUS  
 DOCUMENT NUMBER: 134:161880  
 TITLE: cDNAs encoding the Flt-3 receptor ligand and there use  
 INVENTOR(S): Hermanson, Gary George  
 PATENT ASSIGNEE(S): Vical Inc., USA  
 SOURCE: PCT Int. Appl., 148 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001009303	A2	20010208	WO 2000-US20679	20000731
WO 2001009303	A3	20010816		

W: CA, JP, US  
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: US 1999-146170P P 19990730  
 IT 299207-54-8, GAP-DMORIE  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (in delivery of vector vaccines; cDNAs encoding Flt-3 receptor ligand and there use as adjuvants in vector vaccines)  
 RN 299207-54-8 CAPLUS  
 CN 1-Propanaminium, N-(2-aminoethyl)-N,N-dimethyl-2,3-bis[(9Z)-9-tetradecenyl]oxy]-, bromide (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



● Br<sup>-</sup>

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS ON STN  
 AB The invention provides adjuvants, immunogenic compns., and methods useful for polynucleotide-based vaccination and immune response. In particular, the invention provides an adjuvant of cytofectin:co-lipid mixture wherein cytofectin is GAP-DMORIE.

ACCESSION NUMBER: 2000:707018 CAPLUS  
 DOCUMENT NUMBER: 133:280556  
 TITLE: Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines  
 INVENTOR(S): Wheeler, Carl J.  
 PATENT ASSIGNEE(S): Vical Incorporated, USA  
 SOURCE: PCT Int. Appl., 72 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000057917	A2	20001005	WO 2000-US8282	20000324
WO 2000057917	A3	20010104		

W: CA, JP, US  
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE  
 EP 1165140 A2 20020102 EP 2000-919777 20000324  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI  
 JP 2002540173 T2 20021126 JP 2000-607666 20000324  
 US 6586409 B1 20030701 US 2000-534943 20000324  
 US 2003191082 A1 20031009 US 2003-391216 20030319  
 PRIORITY APPLN. INFO.: US 1999-126340P P 19990326  
 US 2000-534943 A3 20000324  
 WO 2000-US8282 W 20000324  
 US 2001-937604 A1 20010926

IT 299207-54-8, GAP-DMORIE  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (adjuvant compns. containing cytofectin:co-lipid mixts. and methods for enhancing immune responses to polynucleotide-based vaccines)  
 RN 299207-54-8 CAPLUS  
 CN 1-Propanaminium, N-(2-aminoethyl)-N,N-dimethyl-2,3-bis[(9Z)-9-tetradecenyl]oxy]-, bromide (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



● Br<sup>-</sup>

=> logoff y  
COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
20.09	212.19

SINCE FILE	TOTAL
ENTRY	SESSION
-2.08	-6.24

STN INTERNATIONAL LOGOFF AT 17:42:56 ON 19 FEB 2004

L Number	Hits	Search Text	DB	Time stamp
1	10	((("5,264,618") or ("5,334,761") or ("5,459,127") or ("5,580,859") or ("5,589,466") or ("5,641,665") or ("5,676,954") or ("5,693,622") or ("5,703,055") or ("6,147,055") or ("6,235,310B1"))).PN.	USPAT; US-PGPUB	2004/02/19 18:28
2	11	((("5,264,618") or ("5,334,761") or ("5,459,127") or ("5,580,859") or ("5,589,466") or ("5,641,665") or ("5,676,954") or ("5,693,622") or ("5,703,055") or ("6,147,055") or ("6,235,310"))).PN.	USPAT; US-PGPUB	2004/02/19 19:17
3	1	("20030091544").PN.	USPAT; US-PGPUB	2004/02/19 18:33
4	1	("20030191082").PN.	USPAT; US-PGPUB	2004/02/19 18:43
5	2	((("6586409") or ("6670332"))).PN.	USPAT; US-PGPUB	2004/02/19 19:17
6	12	((("5,264,618") or ("5,334,761") or ("5,459,127") or ("5,580,859") or ("5,589,466") or ("5,641,665") or ("5,676,954") or ("5,693,622") or ("5,703,055") or ("6,147,055") or ("6,235,310") or ("6,399,588"))).PN.	USPAT; US-PGPUB	2004/02/19 19:19
7	459539	GAP-	USPAT; US-PGPUB	2004/02/19 19:19
9	0	GAP-DMORIE and (((("5,264,618") or ("5,334,761") or ("5,459,127") or ("5,580,859") or ("5,589,466") or ("5,641,665") or ("5,676,954") or ("5,693,622") or ("5,703,055") or ("6,147,055") or ("6,235,310") or ("6,399,588"))).PN.)	USPAT; US-PGPUB	2004/02/19 19:20
8	4	GAP-DMORIE	USPAT; US-PGPUB	2004/02/19 19:20